Idiopathic Hypersomnia in the USA: Why Diagnosis and Treatment Are Still So Hard to Access
The United States is further ahead than most countries on idiopathic hypersomnia. It has precise ICD-10 codes, an AASM clinical guideline, and Xywav, the world’s only FDA-approved IH treatment (approved August 2021). Yet Americans with IH still wait up to nine years for a diagnosis, and 57 percent of surveyed providers admit to misdiagnosing the condition, most often as depression or anxiety. The barriers here are less about whether treatment exists and more about whether you can reach it: expensive two-night sleep studies, an unreliable MSLT, sleep specialists concentrated in metro areas, prior authorization and step therapy requirements, a roughly $100,000 annual list price for the one approved drug, and years of national stimulant shortages driven by DEA production quotas. Everything other than Xywav is prescribed off-label, which gives insurers an easy reason to deny. The most underused tool patients have is the appeals process, including binding external review. Pitolisant, solriamfetol, and orexin-targeting drugs are advancing through the pipeline.